Prostate-specific antigen kinetics in localized and advanced prostate cancer

BJU International

Volumn 103, Issue 5, 2009, Pages 578-587

  Fitzpatrick, John M ^a   Banu, Eugeniu ^b   Oudard, Stephane ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Prostate cancer; Prostate specific antigen; Prostatectomy; PSA; Radiotherapy; Survival

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; MITOXANTRONE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; SWOG 9916; TAX 327; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

ADULT; AGED; EARLY DETECTION OF CANCER; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 60449106419     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08345.x     Document Type: Short Survey

References (74)

1. Rao AR, Motiwala HG, Karim OM. The discovery of prostate specific antigen. BJU Int 2008 101 : 5 10
2. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987 317 : 909 16
3. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 324 : 1156 61
4. Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992 147 : 841 5
5. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003 289 : 1414 20
6. Boyle P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int 2003 92 : 191 9
7. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - What we have learned and where we are going. J Urol 1999 162 : 293 303
8. Söletormos G, Semjonow A, Sibley PE et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005 51 : 1342 51
9. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≥4.0 ng per millilitre. N Engl J Med 2004 350 : 2239 46
10. Damber J-E, Aus G. Prostate cancer. Lancet 2008 371 : 1710 21
11. De Angelis G, Rittenhouse HG, Mikolajczyk BA et al. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 2007 9 : 113 23
12. Cooner WH, Mosley BR, Rutherford CL et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990 143 : 1146 52
13. Labrie F, Dupont A, Suburu R et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992 147 : 846 51
14. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997 277 : 1452 5
15. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992 267 : 2215 20
16. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994 152 : 1163 7
17. Yu X, Han M, Loeb S et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol 2006 176 : 2427 31
18. King CR, Freedland SJ, Terris MK et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007 69 : 732 7
19. Connolly D, Black A, Murray L J et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007 52 : 1044 51
20. Moul JW, Sun L, Hotaling JM et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007 177 : 499 503
21. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006 98 : 529 34
22. Wolters T, Roobol MJ, Bangma CH, Schröder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2008 March 11. [Epub ahead of print]
23. Ulmert D, Serio AM, O'Brien MF et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008 26 : 835 41
24. Connolly D, Black A, Murray LJ et al. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis. BJU Int 2008 101 : 1507 12
25. Eggener SE, Yossepowitch O, Roehl KA et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008 71 : 1016 9
26. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
27. Bianco FJ, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('Trifecta'). Urology 2005 66 (Suppl. 5A 83 94
28. D'Amico AV, Moul J, Carroll PR et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003 21 : 2163 72
29. Kattan MW, Eastham JA, Stapleton AM et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998 90 : 766 71
30. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999 17 : 1499 507
31. D'Amico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
32. Sengupta S, Myers RP, Slezak JM et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005 174 : 2191 6
33. D'Amico AV, Renshaw AA, Sussman B et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7
34. Bianco FJ Kattan MW, Scardino PT. PSA velocity and prostate cancer. N Engl J Med 2004 351 : 1800 2
35. Loeb S, Sutherland DE, D'Amico AV. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008 72 : 1116 20
36. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001 57 : 476 80
37. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993 72 : 2638 43
38. Stephan C, Kramer J, Meyer H-A et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007 99 : 1427 31
39. Sengupta S, Slezak JM, Blute ML et al. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology 2006 67 : 408 9
40. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006 106 : 1047 53
41. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006 176 : 1927 37
42. Arlen PM, Bianco F, Dahut WL et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008 179 : 2181 6
43. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
44. Roberts SG, Blute ML, Bergstralh E J et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001 76 : 576 81
45. D'Amico AV, Moul J, Carroll PR et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004 172 : S42 7
46. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
47. Zelefsky MJ, Ben-Porat L, Scher HI et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005 23 : 826 31
48. Zhou P, Chen M-H, McLeod D et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005 23 : 6992 8
49. D'Amico AV, Chen MH, Roehl KA et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005 23 : 4975 9
50. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
51. Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006 24 : 3984 90
52. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989 141 : 1088 90
53. Oosterlinck W, Mattelaer J, Casselman J et al. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Acta Urol Belg 1997 65 : 63 71
54. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
55. Berthold D, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008 26 : 242 5
56. Kuriyama M, Wang M, Lee C et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981 41 : 3874 6
57. Kelly WK, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993 11 : 607 15
58. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy of hormone-refractory prostate cancer. J Clin Oncol 1998 16 : 1835 43
59. Dowling AJ, Czaykowski PM, Krahn MD et al. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000 163 : 1481 5
60. Small EJ, McMillan A, Meyer M et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end-points and survival. J Clin Oncol 2001 19 : 1304 11
61. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006 98 : 516 21
62. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007 25 : 3965 70
63. Fossa SD, Vaage S, Letocha H et al. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered. Scand J Clin Oncol 2002 36 : 34 9
64. Olbert PJ, Hegele A, Kraeuter P et al. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006 17 : 993 6
65. Thuret R, Massard C, Gross-Goupil M et al. The postchemotherapy PSA surge syndrome. Ann Oncol 2008 19 : 1308 11
66. Nelius T, Klatte T, de Riese W et al. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol 2008 40 : 97 104
67. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 26 : 1148 59
68. Hussain MH, Goldman B, Tangen CM et al. Use of prostate-specific antigen progression (PSA-P) to predict OS (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. J Clin Oncol 2008 26 (Suppl. 4565. Abstract 5015
69. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17 : 3461 7
70. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006 68 : 565 9
71. Oudard S, Banu E, Scotte F et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007 18 : 1828 33
72. Oudard S, Medioni J, Scotte F et al. What is the real impact of bone pain on survival in patients with hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009 in press
73. Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007 13 : 6396 403
74. Banu E, Banu A, Medioni J et al. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. Prostate 2007 67 : 1543 9